Cardiovascular Diseases, Inflammation, Obesity
Conditions
Brief summary
The specific aim of this study is to determine molecular pathways that differentiate metabolically healthy vs unhealthy human phenotypes, and to investigate the therapeutic potential of pro-resolving lipids. Investigators will recruit volunteers that are metabolically healthy or unhealthy that fall within three BMI ranges: lean (18.-24.9 kg/m2), overweight (25.0-29.9 kg/m2) and obese (\>30.0 kg/m2). Investigators hypothesize that metabolically healthy individuals have a superior endogenous capacity to regulate an inflammatory/resolving response.
Interventions
None listed
Sponsors
University of Aarhus
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Informed signed consent has been obtained from the volunteer. * The volunteer has a BMI greater than 18.5 kg/m2 * Men and women over the age of 18 are included.
Exclusion criteria
* The study staff contacting a potential participant perceives that the individual has difficulty understanding the information. * An MD determines that the individual is on too many medications to participate. * The individual takes a medication that is approved by the MD, but he/she is not willing or not able to wait with any potential morning medication until after their fasted blood-draw. * The individual states that they have increased bleeding tendency or are using anti-coagulant (blood thinning) medication. * The individual has some form of chronic inflammation. * The individual regularly uses medication that affects inflammatory resolution (e.g., low-dose aspirin). * The individual uses immunosuppressive drugs (e.g., methotrexate). * The individual regularly consumes fish oils (omega 3). * The individual has significant gastrointestinal problems. * The individual smokes or uses chewing tobacco. * The individual has been drinking alcohol two days before the study visit. * The individual has tattoos or body piercings on the forearms and / or the stomach that can affect the examination. * The individual does not follow instructions given in the research study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Inflammation and resolution status measurements in different metabolic phenotypes | September 2028 | Quantifiable inflammatory resolution by measurement of IL-6 cytokine levels in the acute vs the resolving phase of blister formation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Systemic low-grade inflammation measurement in different phenotypes | September 2028 | Measurement of plasma C-reactive protein |
Countries
Denmark
Contacts
Primary ContactEmma Börgeson, PhD
Outcome results
None listed